Tag Archives: therapeutics

Kuehne+Nagel takes responsibility of global distribution of Covid-19 Vaccine Moderna

New arrangement leverages Kuehne+Nagel’s global solutions for pharma & healthcare logistics (PRESS RELEASE) CAMBRIDGE, MA, U.S.A. / SCHINDELLEGI, 7-Jan-2021 — /EuropaWire/ — Global transport and logistics company Kuehne+Nagel announces international supply chain arrangement with Moderna, Inc. (NASDAQ:MRNA), a biotechnology company … Read the full press release

Sanofi announces second collaboration as it strives to develop a novel COVID-19 vaccine candidate

(PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur collaborates with Translate Bio (NASDAQ: TBIO) to develop a novel mRNA vaccine for COVID-19. Both companies will jointly investigate multiple candidates with the goal of advancing an … Read the full press release

Novartis, Pear Therapeutics to work together towards developing new treatments for patients with schizophrenia and multiple sclerosis

Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics  Novartis continues to embrace emerging … Read the full press release

University of Warwick: biotechnology firm VirionHealth receives non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA)

Coventry, UK, 08-Jan-2018 — /EuropaWire/ — VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has won non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA). … Read the full press release

AstraZeneca’s global biologics research and development arm MedImmune completed its acquisition of US-based Amplimmune for $225M plus $275M based on predetermined milestones

London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm, completed its acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology. As previously announced, … Read the full press release